Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04248153 · ClinicalTrials.gov registry record · Phase 2
Optimal Timing of BR55 CEUS of the Ovaries
A Phase 2 study, sponsored by Bracco Diagnostics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04248153 is a Phase 2 study that was terminated before completion, run by Bracco Diagnostics. The registered enrollment target is 3 participants.
The verdict
NCT04248153, a Phase 2 study, was terminated before completion, sponsored by Bracco Diagnostics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is an exploratory, single center, open label, prospective study of BR55 to determine the optimal phase of the menstrual cycle for performing BR55 contrast-enhanced ultrasonography (CEUS) of the target ovary in premenopausal women scheduled to undergo preventative surgery because of high familial/hereditary or genetic risk for ovarian cancer.
Interventions
- DRUG BR55
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-10-14 |
| Est. Completion | 2021-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04248153
The ClinicalTrials.gov registry entry for NCT04248153 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BR55 is the first listed.
NCT04248153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04248153 about?
NCT04248153 is a clinical study titled "Optimal Timing of BR55 CEUS of the Ovaries". This is an exploratory, single center, open label, prospective study of BR55 to determine the optimal phase of the menstrual cycle for performing BR55 contrast-enhanced ultrasonography (CEUS) of the target ovary in premenopausal women scheduled to undergo preventative surgery because of high familia...
What is the current status of trial NCT04248153?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2019-10-14. Estimated completion is 2021-07-31.
What interventions are being tested in trial NCT04248153?
The interventions under investigation include: BR55 (DRUG).
Who is sponsoring clinical trial NCT04248153?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.